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Summary 
CD28 is a 44-kD homodimer expressed on the surface of the majority of human T  cells that 
provides an important costimulus for T cell activation. The biochemical basis of  the CD28 accessory 
signals is poorly understood. Triggering of the T cell antigen receptor (TCR) activates the p21 r~s 
proteins. Here we show that ligation of CD28 by a monoclonal antibody (mAb) also stimulates 
p21  r~s and induces Ras-dependent events such as stimulation of the microtubule-associated protein 
(MAP) kinase ERK2 and hyperphosphorylation of Raf-1. One physiological ligand for CD28 
is the molecule B7-1. In contrast to the effect of CD28 mAb, the present studies show that 
interactions between CD28 and B7-1 do not stimulate p21 r~s signaling pathways. Two substrates 
for TCR-regulated protein tyrosine kinases (PTKs) have been implicated in p21  r~ activation in 
T cells: p95  V~v and a 36-kD protein that associates with a complex of Grb2 and the Ras exchange 
protein Sos. Triggering CD28 with both antibodies and B7-1 activates cellular PTKs, and we 
have exploited the differences between antibodies  and B7-1 for p21  ~'s activation in an attempt 
to identify critical PTK-controlled events for Ras activation in T cells. The data show that antibodies 
against TCR or CD28 induce tyrosine phosporylation of both Vav and p36. B7-1 also induces 
Vav tyrosine phosphorylation but has no apparent effect on tyrosine phosphorylation of the Grb2- 
associated p36 protein. The intensity of the Vav tyrosine phosphorylation is greater in B7-1 than 
in TCR-stimulated cells. Moreover the kinetics of Vav tyrosine phosphorylation is prolonged 
in the B7-1-stimulated cells. These studies show that for CD28 signaling, the activation of p21  ~s 
correlates more closely  with p36 tyrosine phosphorylation than with Vav tyrosine phosphorylation. 
However, the experiments demonstrate that Vav is a major substrate for B7-activated PTKs and 
hence could be important in CD28  signal transduction pathway. 
T  lymphocyte activation is initiated when the T cell en- 
counters  antigen/major histocompatibility molecules 
presented to the T cell on the surface of an APC. The signals 
generated by the TCR ensure the immune specificity of T 
cell activation, but for a full immune response there is a re- 
quirement for additional signals triggered by accessory mol- 
ecules present on the surface  of the APC (1, 2). A large number 
of molecules participate in the interaction between the T cell 
and the APC, including molecules like CD4 and CD8,  as 
well as adhesion molecules and integrins such as CD2 and 
LFA-1. However, there is considerable evidence that CD28, 
a 44-kD homodimeric glycoprotein expressed by most ma- 
ture T lymphocytes, is one of the more important receptors 
for the generation of the "second signal" for T cell activation 
(3). Two physiological ligands for CD28 have been described: 
B7-1 (B7/BB1) and B7-2 (B70) (4-8). These B7 molecules 
are expressed  by APCs and their interactions with CD28 have 
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been shown to costimulate T ceils in cooperation  with en- 
gagement of the TCR (8,  9). 
Triggering of the TCR/CD3 complex initiates a cascade 
of biochemical events, the earliest of which is activation of 
intracellular protein tyrosine kinases (PTKs) t (10). This ac- 
tivation of PTKs appears to be absolutely required for all sub- 
sequent T  cell responses (11, 12). One substrate for TCR- 
stimulated  PTKs is an inositol lipid-specific phospholipase 
C, PLC3'I  (13). Hence PTKs enable the TCR to regulate 
the  hydrolysis  of membrane phosphoinositides  (Ptdlns), 
1 Abbreviations used in this  paper: EGFR, epidermal  growth  factor  receptor; 
GST, glutathione~S-transferase;  MAP,  microtubule-associated  protein: MBP, 
myelin  basic protein; PDBu, phorbo112, 13-dibutyrate;  PKC, protein  kinase 
C; PLC, phospholipase  C; Ptdlns,  phosphoinositides;  lYFK, protein  tyrosine 
kinase; SH, Src homology. 
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nine kinase,  protein  kinase C  (PKC)  (14-16),  and inositol 
polyphosphates  that  regulate intracellular  Ca  2+. 
The TCR also stimulates the guanine nucleotide binding 
proteins p21TM (17,  18), which then couple the TCR to the 
MAP kinase ERK2 and hence to the regulation of transcrip- 
tional factors such as AP-1, NFAT, and the IL-2 gene (19-21). 
TCR activation of p21TM requires cellular PTK function and 
recent studies have identified two PTK substrates, Vav and 
a 36-kD  membrane  protein,  as potential  mediators  of the 
TCR/p2Y as  link  (22,  23).  In  fibroblasts,  PTKs  stimulate 
p2Y  a~ by regulating the activity of Ras GTP/GDP exchange 
proteins.  T  cells express two potential Ras guanine nucleo- 
tide exchange proteins:  Sos, a homologue of the Drosophila 
Son of Sevenless  gene product (24),  and Vav, which has in 
vitro guanine nucleotide exchange activity for Ras. It is pro- 
posed that the activity of Vav is regulated by tyrosine phos- 
phorylation  (22).  In contrast,  Sos regulates p21 ras when it 
is recruited to the cell membrane by the adaptor protein Grb2 
(25-29). Grb2 is composed of two Src homology (SH)3 do- 
mains  that  bind  to Sos and an SH2 domain  that  interacts 
with tyrosine phosphoproteins (25). In TCR-stimulated cells, 
there is a rapid formation of a complex between Sos/Grb2 
and a 36-kD membrane protein that is substrate for the TCR- 
induced PTKs (23). This complex is analogous to the Sos/Grb2 
epidermal  growth  factor  receptor  (EGFR)  complex  that 
localizes Sos to the plasma membrane  in fibroblasts. 
Little is known about the CD28 costimulatory signals rel- 
ative to the wealth of knowledge about TCR signal trans- 
duction.  CD28 signal transduction  does appear to be con- 
trolled by PTKs and it has been described that CD28 regulates 
PLC3,1 tyrosine phosphorylation, Ptdlns hydrolysis, and in- 
tracellular Ca  2+ levels (30-32). However, calcium signaling 
pathways in  T  cells are  sensitive  to  inhibition  by the im- 
munosuppressive drugs cyclosporin A (CsA) and FKS06 and 
one characteristic of CD28 costimulatory signals is that they 
are not  susceptible to inhibition  by CsA (33).  The role of 
Ras in CD28 signaling has never been studied, although re- 
cent studies have shown unequivocally that p2Y  a~ function 
is essential for T cell activation. Moreover, T cells transfected 
with v-Ha-ras, a constitutively activated Ras mutant, are hyper- 
responsive to TCR ligation (20, 21). This latter observation 
in particular has prompted us to examine the effect of CD28 
on the p21TM pathway. 
The present data show that there is the potential for CD28 
to couple to p21TM because ligation  of CD28 with  specific 
antibodies induces the accumulation of Ras/GTP complexes, 
the  hyperphosphorylation  of a  MAPkinase  kinase  kinase 
(MAPKKK) Raf-1 and the activation of a MAP kinase ERK2. 
CD28 antibodies also induce the tyrosine phosphorylation 
of Vav and the Sos/Grb2-associated protein, p36. In contrast, 
the costimulatory interaction between CD28 and its natural 
ligand B7-1 did not induce the Ras signaling pathway. B7-1 
was able to induce tyrosine phophorylation  of Vav and the 
failure to activate Ras was correlated with a failure of B7-1 
to induce tyrosine phosphorylation  of p36.  Studies of Vav 
tyrosine phosphorylation revealed that TCR ligation induces 
a relatively weak, rapid, and transient phosphorylation of Vav. 
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In contrast,  the Vav tyrosine phosphorylation monitored in 
B7-1-activated cells  is markedly stronger  and prolonged. 
Materials and Methods 
Cell Lines.  The subclone of theJurkat T leukemia cells,  J.H6.2 
was maintained  in  RPMI  1640 supplemented  with  10%  heat- 
inactivated FCS. TheJurkat J.H6.2 cell line has been described (34) 
and this cell line does not express the other ligand for B7 mole- 
cules, CTLA-4 (data not shown), huB7 + L cells were obtained by 
transfection of the human B7-1 cDNA in routine L cells (A. Truneh, 
manuscript in preparation) and selected by G418 resistance. These 
cells were maintained in DMEM supplemented with  10% FCS, 
penicillin, streptomycin,  and glutamine.  For T cell stimulations, 
L cells were detached from the tissue culture flasks by incubation 
with  trypsin/EDTA,  washed once in PBS then  once in RPMI 
medium, and resuspended in RPMI medium. Untransfected L cells 
were used as control  cells. 
Antibodies and Fusion Proteins.  mAb UCHT1 reactive with the 
e chain of the human TCR/CD3 antigen complex and mAb CD28.2 
or CD28.5  reactive with the human  CD28 molecule (34) were 
purified from hybridoma supernatants by protein A-Sepharose. To 
stimulate cells, UCHT1 or CD28.2 were used at  10 #g/ml and 
CD28.5 at 50 #g/ml. The ascites of the anti-B7 mAb 104 is a kind 
gift ofJ. Banchereau (Schering Plough, Dardilly, France) and was 
used at  1 in 100. 
The mAb Y13-259 was used to immunoprecipitate  p21TM (17). 
The rabbit antiserum  66 was used to detect p74  '~q in immuno- 
blotting (35) and the rabbit antiserum 122 was used to immunopre- 
cipitate and to detect p42 ~k-~ (36). The monoclonal antiphospho- 
tyrosine antibody 4G10 was purchased from Upstate Biotechnology 
Inc. (Lake Placid, NY). The monoclonal anti-Grb2 antibody was 
purchased from AFFINITI (Nottingham, UK). The antipeptide 
antiserum VAV-1 used to immunoprecipitate and detect in immuno- 
blotting the p95  ray protein  was described previously (37). 
The  fusion  protein  encoding  glutathion-s-transferase  (GST) 
mSosl  COOH  terminus  (residues 1135-1336) was coupled  to 
glutathione  beads and used to purify Grb2 as described (23, 26). 
Assay ofp2I ~s Activation.  p21 ras proteins were immunoprecip- 
itated  with the antibody  Y13-259 from cells in which  guanine 
nucleotides were labeled biosynthetically with [32p]orthophosphate 
(17). Labeled guanine nucleotides bound to p21 r~ proteins  were 
eluted, separated by TIC, and then quantitated by direct scanning 
for B emissions (AMBIS Systems Inc., San Diego, CA).  Results 
are expressed as the percentage of p21 r~ proteins bound to GTP 
relative to total guanine  nucleotides complexed to the protein. 
Immunoloreciloitation and Immunoblotting.  The Jurkat T cells were 
removed from culture, washed twice in RPMI 1640, and suspended 
at 4  x  106 cells/ml in RPMI medium. The cells were prewarmed 
at 37~  for 3 rain. Cells were stimulated at 37~  then pelleted 
in a microcentrifuge, and lysed in a buffer containing 50 mM Hepes 
(pH 7.4), 1% NP-40, 150 mM NaC1, 20 mM NaF, 20 mM iodo- 
acetamide, 1 mM PMSF, 1 #g/ml protease inhibitors (leupeptin, 
pepstatin  A, chymotrypsin),  and 1 mM Na3VO4. 
Acetone-precipitated proteins from cell lysates corresponding to 
4  x  106 Jurkat cells were resolved in either 10% SDS-PAGE (for 
detection of ERK2) or 8% SDS-PAGE standard gels (for detection 
of other proteins). 
For immunoprecipitation,  lysates were clarified and incubated 
with purified anti-Vav antibody coupled to protein A-Sepharose 
or 5/xg of GST fusion protein immobilized on glutathione  beads 
for 2 h at 4oC. Immunoprecipitates  or precipitates were washed 
Tfiggedng four times in 1 ml of lysis buffer and then boiled in reducing SDS 
gel sample buffer for 5 min. Samples were resolved by 8% SDS- 
PAGE standard gels. 
For immunoblotting, membranes  were blocked  and probed with 
specific antibodies. Blots were then incubated with the appropriate 
second antibodies, anti-rabbit IgG or anti-mouse IgG (Amersham 
International, Little Chalfort, UK), all conjugated with horseradish 
peroxidase. Immunoreactive  bands were visualized  by enhanced  che- 
miluminescence (Amersham International). 
Analysis  of MAP  Kinase Activity  in  ERK2  Immunoprecipi- 
tates.  ERK2 was immunoprecipitated with a specific antiserum 
and kinase activity of ERK2 assessed as described previously (36). 
Briefly 4  x  106 Jurkat T cells were stimulated at 37~  as indi- 
cated, then pelleted and lysed in a buffer containing 50 mM Hepes 
(pH 7.4), 1% NP-40, 150 mM NaC1, 20 mM NaF, 20 mM iodo- 
acetamide, 1 mM PMSF, 1 #g/ml protease inhibitors (leupeptin, 
pepstatin A, chymotrypsin), and 1 mM Na3VO4. After 10 min of 
preclearing with protein A insoluble suspension (Sigma Chemical 
Co., St. Louis, MO), then 10 min of preclearing with protein 
A-Sepharose beads (Pharmacia  LKB,  Uppsala, Sweden),  lysates  were 
incubated for 2 h at 4~  with 10 #1 of the 122 antiserum precou- 
pled to 50/zl of a 50% suspension of protein A-Sepharose beads. 
Immunoprecipitates were washed three times with lysis  buffer and 
once with kinase assay buffer  (30  mM  Tris [pH  8],  20  mM 
MgC12, and 2 mM MnC12). In vitro kinase assay  buffer was car- 
ried out for 30 rain at 30~  in 20/~1 of kinase assay buffer sup- 
plemented with 10 #M ATP, 5/zCi y-[32p]ATP, and 10 #g my- 
elin basic protein (MBP) as a substrate. The kinase reaction was 
stopped with 20/A of 2  x  SDS sample buffer and samples were 
run in 15% SDS-PAGE gels. Quantitation of 32p incorporated into 
the MBP protein band was done by/3 radiation scanning of dried 
gels using a scanner (AMBIS Systems Inc.). 
II~2 Production.  Jurkat cells were washed several times in cul- 
ture  medium,  then resuspended at  a  concentration  of 0.5  x 
106/ml. Duplicate cultures (200/zl) in 96-well flat-bottomed plates 
were set up in the presence of saturating concentrations of mAbs 
or PHA (10 #g/ml). Purified PHA was supplied by Industries Bi- 
ologiques Fran~aise (Villeneuve-la-Garenne, France). The L cells 
were used at a concentration of 0.25  x  105/ml. After 18 h, su- 
pernatants were collected and stored at - 80~  for IL-2 assay. IL-2 
concentrations  were measured  by ELISA,  using a commercially  avail- 
able kit (Immunotech S.A., Marseille, France) according to the 
manufacturer's instructions. 
Results 
CD28  Triggering Activates p2I ras in Jurkat  Cells.  T  cells 
can be activated via the CD28 pathway by triggering cells 
with  CD28  antibodies.  To  determine whether  the p21 ras 
guanine nucleotide binding cycle is regulated via the CD28 
molecule,  p21r~/GTP loading experiments were performed. 
Endogenous guanine nucleotides were metabolically labeled 
with [32p]orthophosphate  and p21 ~  protein was immuno- 
precipitated from Jurkat cells exposed to antibodies against 
CD28  or the CD3/TCR complex,  and the phorbol ester 
phorbol 12, 13-dibutyrate (PDBu) that directly activates PKC. 
The  mAb  used  to  trigger  the  CD3/TCR  complex  was 
UCHT1. Two CD28 mAbs were used, CD28.2, which can 
induce a IL-2 secretion in Jurkat cells and CD28.5, which 
is nonfunctional in this respect,  and that apparently binds 
to CD28 without triggering CD28 signal transduction (34). 
The proportion of p21 ~a~ bound to  GTP  (the ratio be- 
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tween  GTP  and  GTP  plus  GDP-labeled  nucleotides  on 
p21 TM) was evaluated by 3 emission scanning of TIC-resolved 
guanine nucleotides eluted from immunoprecipitated ras pro- 
teins. Fig.  1 A  shows that PKC stimulation with PDBu in- 
creased the level of GTP bound to ras from 11% in unstimu- 
lated Jurkat cells to 40% (fourfold). CD28 triggering with 
CD28.2 resulted in a threefold increase in the proportion of 
GTP-bound ras (from 11  to 29%),  this increase  is similar 
to the increase after CD3/TCR triggering with UCHT1. 
The CD28 mAb, CD28.5 did not induce an increase in the 
proportion of GTP-bound ras. The kinetics of the increase 
in the proportion of GTP-bound ras are shown in Fig. 1 C. 
The TCR response  peaked after 1 min, whereas the CD28 
response  was maximal at 5 min. Both TCR and CD28 re- 
sponses could still be detected 30 min after CD3/TCR or 
CD28  stimulation. 
CD28  Triggering Induces the Phosphorylation of ERK2 and 
RAE  In many cell systems, p21 ras couples receptor stimu- 
lated PTKs to Raf-1 and hence to the MAP kinase cascade. 
The predominant MAP kinase in T cells is ERK2 and p21 ras 
plays a crucial role in the TCR/ERK2 link. The activation 
of ERK2 can be monitored by Western blot analysis with 
an ERK2-specific antiserum because the activation of this ki- 
nase requires  its phosphorylation on threonine and tyrosine 
residues and the phosphorylated "active" ERK2 has a reduced 
mobility on SDS-PAGE gels compared with nonphosphor- 
ylated, "inactive" ERK2 (36). The experiment in Fig. 2 shows 
the reduced mobility of ERK2 in Jurkat cells treated with 
the PKC activator,  PDBu, a CD3 mAb UCHT1 and CD28 
mAbs compared with control unstimulated cells. Stimula- 
tion with UCHT1  or CD28.2 rapidly induced a mobility 
shift in the band corresponding to ERK2 that was maximal 
between 5 and 30 min of exposure to the antibody. PDBu 
also induced a rapid shift in ERK2 mobility in Jurkat cells. 
Previous  studies have shown that Raf-1 is activated rapidly 
in TCR- and phorbol ester-stimulated T cells (38). It is also 
well documented that Raf-1 is hyperphosphorylated in re- 
sponse to T cell activation (39, 40) and this hyperphosphory- 
lation of Raf-1 correlates  with activation of the enzyme al- 
though it is apparently not directly involved in mediating 
the increase in Raf-1 enzymatic activity (41). The stimula- 
tion of Raf-1 has been recently shown in peripheral blood 
T cells after CD28 mAb cross-linking (38). Hyperphosphor- 
ylated Raf-1 has reduced mobility on SDS-PAGE gels hence 
to determine whether Raf-1 is hyperphosphorylated in Jurkat 
cells, a Western blot of cell lysates prepared from cells treated 
with UCHT1, CD28 mAbs, or PDBu was probed with a 
Raf-1 antisera. The data in Fig. 2 show the UCHT1, CD28.2, 
and PDBu induce a shift in Raf-1 mobility that is comparable 
with the ERK2 response. The CD28 mAb, CD28.5, which 
does not costimulate T cells, did not induce a detectable hyper- 
phosphorylation of Raf-1 or ERK2. 
B7-1-Transfected  L  Cells Induce Tyrosine Phosphorylation of 
Cellular Substrates and IL-2 Secretion, but Not RAS Activation 
or RAF and ERK2 Phosphorylations.  It has been shown that 
the natural ligand for CD28, B7-1, expressed on the surface 
of Chinese hamster ovary cells can provide costimulation for 
T cells, replacing the effects seen with CD28 mAbs (9). To determine whether IL-2 secretion could be induced by liga- 
tion of CD28 with B7-1 inJurkat cells, the culture superna- 
tants  from cells stimulated  with PHA in the presence of L 
cells  transfected  with  human  B7-1  (huB7 +  L  cells)  or 
CD28.2  mAb were collected  and  assayed for IL-2 produc- 
tion.  A  small amount of IL-2 was detected when the Jurkat 
cells were stimulated with PHA alone (Fig. 3). When CD28.2 
or  huB7 §  L  cells  were  added  to  PHA-stimulated  Jurkat 
cells,  IL-2 secretion was markedly increased  (20-fold).  The 
addition of anti-B7 mAb 104 blocked the stimulation of IL-2 
production  by huB7 +  L  cells. 
The experiment in Fig. 4 A  compares the effect of huB7 + 
L cells, UCHT1, CD28.2,  and PDBu on Ras/GTP loading. 
The data show that PDBu,  UCHT1,  and CD28.2  induced 
an increase  in cellular levels of active Ras/GTP  complexes, 
whereas  huB7 +  L  cells  have  no  effect.  In  parallel  experi- 
ments (Fig.  4 B),  the phosphorylation  of Raf-1  and ERK2 
in B7-1-stimulated T  cells was monitored. UCHT1, CD28.2, 
or PDBu induced an increase of the apparent molecular weight 
of p74 raf-t or p42 erk2. However,  over a  30-min  time course, 
there was no detectable effect of huB7 + L cells on Raf-1 or 
ERK2  electrophoretic  mobility. 
To examine the consequences of CD28 ligation on ERK2 
activity, MBP kinase assays were carried out on MAP kinase 
immunoprecipitates. The data in Fig. 4 C show that UCHT1, 
PDBu,  and CD28.2  induced  an approximate two- to three- 
fold increase in ERK2 kinase activity in Jurkat T cells, whereas 
huB7 §  L  cells  have no  effect. 
It has been described previously that CD28 ligation acti- 
vates cellular PTKs (42,  43).  Accordingly,  we reprobed the 
Raf-1 and ERK2 blots with an antiphosphotyrosine antibody. 
The  data  in  Fig.  4  D  show  that  a  95-kD  tyrosine  phos- 
phoprotein  was detected  in Jurkat  cells within  5  min after 
contact  of the cells with  huB7 + L  cells.  The results  of the 
antiphosphotyrosine  Western blot  show that  the  failure to 
detect an effect of huB7 § L cells on Raf-1 or ERK2 was not 
due  to  the  failure  of B7-1  to  trigger  CD28.  In  these  ex- 
perimental  conditions,  we  can  not  detect  tyrosine  phos- 
phoproteins  in lysates from L  cells alone and the pattern of 
tyrosine phosphorylations in Jurkat cells was the same with 
paraformaldehyde-fixed  huB7 +  L  cells or  not  fixed huB7 + 
L cells (data not shown). The 95-kD tyrosine phosphoprotein 
Figure  1.  p21  ras is activated in Jurkat  cells stimulated by the CD28 
mAb CD28.2.  (A) TLC of the nucleotides eluted from immunoprecipi- 
tates of p21  r~ from [32p]orthophosphate-labded  Jurkat cells. The ceils were 
unstimulated (control) or stimulated for 10 rain with a CD3 mAb UCHT1 
(10/zg/ml),  CD28 mAbs, (CD28.2 [10 gg/ml] or CD28.5 [50 gg/ml]), 
and PDBu (100 ng/ml)  before lysis and immunoprecipitations of p21  r~s 
with Y13-259 as described. The position at which GTP and GDP stan- 
dards ran is indicated. (B) The figure shows the quantitation of guanine 
nucleotides of p21=s by direct scanning of 3 radiation from the TIC in 
A. Data are expressed as percentage of GTP to ras with respect to the 
total amount of guanine nucleotide on p21  r'~. The data given are repre- 
sentative of the results obtained from at least five experiments. (C) Ki- 
netics of p21=~ activation after T cell activation with UCHT1 or CD28.2. 
Time-course showing the nudeotides bound to Ras upon stimulation of 
Jurkat cells with UCHT1 (10/~g/ml) or CD28.2 (10 #g/ml). Nucleotides 
were separated  by TLC and quantitated by direct scanning for ~ radiation. 
1070  Ras Activation after CD28 Triggering Figure  2.  CD28 mAb  CD28.2 induces a  hyper- 
phosphorylation  of  Raf-1 and a phosphorylation  of  MAPK 
Erk2. Jurkat cells were stimulated with UCHT1 (10 
/~g/ml), CD28.2 (10 /~g/ml), CD28.5 (50 /zg/ml), or 
PDBu (100 ng/ml) for the indicated  time. Whole cell ly- 
sates were probed with the Raft antibody  66 (top) or the 
ERK2 antibody  122, which recognizes  p42  ~k3 (bottom). 
This experiment was performed  three times with iden- 
tical results. 
was also detected after stimulation of T cells with UCHT1 
or CD28.2. However, the pattern and intensity of tyrosine 
phosphorylation in TCR-  or CD28-activated  T  cells was 
different. Some tyrosine phosphoproteins were common to 
TCR-  and CD28-induced cells but in general the level of 
phosphorylation was stronger in the TCR-activated cells. 
There was one tyrosine phosphoprotein of approximately 
65 kD that was detected in the B7-1 stimulated cells but not 
in TCR-stimulated Jurkat. This molecule could be a unique 
substrate for CD28-activated PTKs. 
Stimulation of  Jurkat  Cells through the CD28 Molecule by a 
Specific mAb or the Ligand B7-1 Induces a Tyrosine  Phosphoryla- 
tion of VAV.  One candidate for the 95-kD  tyrosine phos- 
phoprotein in the TCR- and CD28-activated cells is p95 Vav, 
which is known to be tyrosine-phosphorylated in response 
to TCR triggering (37,  44).  The stimulation of p21 ra' re- 
quires cellular PTK function, and since Vav has been described 
to act as a guanine nucleotide exchange protein for ras in vitro, 
it has been proposed that Vav tyrosine phosphorylation is 
an important event for Ras regulation (22). We therefore com- 
pared the tyrosine phosphorylation of Vav in TCR- or CD28- 
activated cells. For these experiments, antiphosphotyrosine 
immunoblots were performed on Vav immunoprecipitates. 
In the experiment shown in Fig. 5 A, a weak basal tyrosine 
phosphorylation of  Vav was detectable in Jurkat cells. UCHT1 
and CD28.2 both induced a rapid increase  in Vav tyrosine 
phosphorylation that was maximal at 1 min in the TCR- 
activated cells and 5 min in the CD28.2-stimulated popula- 
tion. There was no change in Vav tyrosine phosphorylation 
in cells treated with CD28.5. 
The data in Fig. 5 B show the effect of the CD28 ligand 
B7-1 on the tyrosine phosphorylation of Vav. In this experi- 
ment, the immunoblots were probed with an antiphospho- 
tyrosine antibody and then reprobed with an anti-Vav antibody 
to control the presence of Vav in all immunoprecipitates. The 
data show that huB7 + L  cells do not express  Vav but are 
able to induce a strong tyrosine phosphorylation of Vav in 
T  cells, that was detectable within 30 s and maintained for 
10 min. Untransfected L ceils did not have this effect. The 
level of tyrosine phosphorylated Vav in cells triggered by B7-1 
was markedly higher than the maximal phosphorylation seen 
in cells activated with UCHT1  or CD28.2  (Fig.  5 B).  In 
addition, the increase in Vav tyrosine phosphorylation was 
a more prolonged response  in the B7-1-stimulated cells. 
The COOH-terminal  Domain of SOS Complexes with the 
p36 Tyrosine  Phosphoprotein inJurleat Cells Stimulated by CD28 
mAb~ but Not by B7-1 Ligation.  Very recently, it was shown 
that TCR activation of ras might be controlled, at least in 
part, by a mechanism involving the formation of a complex 
of the Ras exchange protein Sos, Grb2,  and a membrane- 
bound protein of 36 k_D that is tyrosine-phosphorylated in 
TCR-activated cells (23). The data in Fig. 6 compare the ability 
of CD28 ligation and TCR triggering to induce the tyrosine 
phosphorylation of the 36-kD  Grb2-associated protein. 
Grb2 is composed of two SH3 domains that bind to Sos 
and  an  SH2  domain  that  interacts  with  tyrosine  phos- 
phoproteins. To look at the ability of  tyrosine-phosphorylated 
proteins to interact with the Grb2-SH2 domain, we have used 
a GST fragment of the proline-rich COOH-terminal domain 
of Sos (amino acids 1135-1336) immobilized on glutathione 
agarose beads to precipitate Grb2- and Grb2-binding proteins 
from the lysates of resting and stimulated Jurkat cells. The 
Grb2 complexes are then analyzed by Western blotting with 
an antiphosphotyrosine antibody. The GST/Sos fragment used 
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Figure  3.  1I.-2  production  in response to CD28 mAb 
or B7-1-expressed  L cells  in PHA-stimulated  Jurkat cells. 
Jurkat cells  were  stimulated  by PHA alone  or with CD28 
mAb  CD28.2 (10  ~g/ml) or B7-1-expressed L cells 
(huB7  + L cells at a ratio of 1:20). Controls  were added 
using untransfected  L cells or huB7  + L cells  preincubated 
with anti-B7-1 mAb, 104 (1:100 of ascites) for 5 min.  After 
18 h, supernatants  were assayed  for Ib2 as described in 
Materials and Methods.  The experiment shown  is repre- 
sentative of  three separate experiments. Results are 
presented  as means +_ standard  errors of  the means  of  dupli- 
cate determinations. 
1071  Nun,s  et al. Figure  4.  Interaction of CD28 with huB7  + L cells induces tyrosine phosphorylation of cellular proteins, but not Ras activation, Erk2 activation, 
Raf-1 and Erk2 phosphorylations. L cells were detached from tissue culture plates and washed once in PBS then twice in RPMI medium. Jurkat cells 
were unstimulated (control) or stimulated with UCHT1 (10/~g/ml), CD28.2 (10/~g/ml), PDBu (100 ng/ml) for 10 min and L cells expressing B7-1 
(huB7 + L cells) or not expressing B7-1 (L cells) (at a ratio of 1:2) for the indicated time. (A) Before stimulation, Jurkat cells were labeled with [32p]or- 
thophosphate. After stimulation, an assay of p21  ras activation was performed. The figure shows the quantitation of guanine nucleotides of p21  r~s by 
direct scanning of/3 radiation. Data are expressed as percentage of GTP to ras with respect to the total amount of guanine nucleotide on p21  ras. (B) 
Whole cell lysates were probed with the anti-Raft antibody 66 (top) or the anti-Erk antibody 122 (bottom). (C) Regulation of Erk2 in Jurkat cells. 
The cells were unstimulated (control) or stimulated with  UCHT1 (10 #g/ml),  CD28.2 (10/zg/ml),  PDBu (100 ng/ml),  L cells (at a ratio of 1:2) 
for 10 min and L cells expressing B7-1 (huB7  + L cells) (at a ratio of 1:2) for the indicated time. A MBP phosphorylation assay was performed as 
indicated in Materials and Methods. Data are expressed as cpm of 32p incorporated into MBP as assessed by Ambis /3 scanning. (D) Immunoblots 
from B were stripped of antibody and redevetoped with  the antiphosphotyrosine 4G10 antibody. The position of molecular mass markers are shown 
on the left; arrowheads indicate the position of 65- and 95-kD phosphoproteins. 
in these experiments binds to the SH3 domains of Grb2 and 
competes for the binding of  endogenous Sos and thereby allows 
the precipitation of endogenous Grb2 and any proteins com- 
plexed  to  the  Grb2-SH2  domain  (23). 
The interaction between Grb2 and GST fusion protein of 
the COOH-terminal region of Sos is shown from Jurkat cell 
lysates,  using an anti-Grb2 antibody in immunoblotting (Fig. 
6,  bottom).  When the Grb2 precipitates are probed with an- 
tiphosphotyrosine antibodies in a Western blot analysis (Fig. 
6, top),  a 36-kD tyrosine phosphoprotein, p36, is seen in the 
Sos/Grb2  complexes isolated  from TCR-stimulated Jurkat 
cells,  p36 is also present in the Sos/Grb2 complex after stim- 
ulation with CD28.2, but was not detectable when the Jurkat 
cells were unstimulated.  The kinetics of p36 tyrosine phos- 
phorylation in TCR-stimulated cells are comparable with the 
kinetics of Vav tyrosine phosphorylation. The huB7 + L cells 
1072  Ras Activation after CD28 Triggering Figure 6.  CD28 mAb CD28.2, but not B7-1 ligation induces tyrosine 
phosphorylation of a 36-kD tyrosine protein that binds to the Grb2 SH2 
domain. Jurkat cells (8  x  106)  were stimulated with UCHT1 (10/zg/ml), 
CD28.2 (10/xg/ml), and L cells expressing  B7-1 (huB7  + L cells) or not 
expressing B7-1 (L cells) (at a ratio of 1:2) for the indicated time. Proteins 
were precipitated  from the postnuclear  cell  lysates  with GSTmSosl-COOH 
terminus fusion protein immobilized on glutathione beads. Bound pro- 
teins were analyzed  with antiphosphotyrosine  4G10  antibody (top) or anti- 
Grb2 antibody (bottom).  p36 is indicated by an arrowhead. 
Figure  5.  CD28 mAb CD28.2 or B7-1 ligation induces rapid tyrosine 
phosphorylation  of the ray protooncogene product in Jurkat cells. Vav im- 
munoprecipitates  were  performed  from NP40-soluble  cellular  proteins. (A) 
Jurkat cells  were stimulated  with UCHT1 (10 ~g/ml), CD28.2 (10/~g/ml), 
and CD28.5 (50/.tg/ml) for the indicated  time. (B) Jurkat cells  were stimu- 
lated with UCHT1 (10/tg/ml), CD28.2 (10/~g/ml), and L cells  expressing 
B7-1 (huB7  + L cells) or not expressing B7-1 (L cells) (at a ratio of 1:2) 
for the indicated  time. In the penultimate lane orB, a Vav immunoprecipi- 
tate was performed on a lysate of 2  x  106 huB7 + L cells alone, p95  v~v 
was detected with antiphosphotyrosine 4G10 antibody (top, A  and B) or 
anti-Vav antibody, VAV-1 (bottom,  A  and B). 
trigger a strong tyrosine phosphorylation of Vav (Fig. 5) but 
did not induce the tyrosine phosphorylation of p36. The data 
in Fig. 6 (top) show antiphosphotyrosine immunoblots of Grb2 
isolated from Jurkat cells exposed to huB7 + L cells for 10-20 
min. Analysis of earlier time points also failed to detect B7- 
1-induced tyrosine phosphorylation of p36 (data not shown). 
Discussion 
The stimulation of the CD28 molecule delivers important 
costimulatory signals for T  cell activation (3). CD28 signaling 
pathways and the biochemical basis of this costimulatory func- 
tion are poorly understood. Recent studies have shown that 
p21TM proteins  have an  important  function  in  TCR  signal 
transduction  (20,  21).  The object of the present  study was 
to determine whether p21  ras is involved in CD28  signaling. 
The activation of p21  ras involves the  accumulation  of Ras- 
GTP complexes. Accordingly, the experiments herein com- 
pared the ability of CD28 mAbs or the human B7-1 molecule 
to stimulate p21  TM and p2V  ~ dependent functions such as the 
hyperphosphorylation of Raf-1 and the activation of the MAP 
kinase ERK2. The data presented show that there is the poten- 
tial for CD28  to regulate the Ras signaling pathway.  Thus 
CD28.2, a functionally agonistic CD28 mAb, induces a rapid 
conversion of p2PffGDP  to p21~s/GTP.  CD28.2  also  in- 
duces  a  hyperphosphorylation of a  MAPKKK,  Raf-1,  and 
stimulates  the MAP kinase ERK2.  One natural ligand  for 
CD28 is the B7-1 molecule which, when expressed in fibro- 
blasts,  can provide costimulatory signals for IL~  secretion 
in T  ceUs (9). The present data show that CD28 interactions 
with the B7-1 molecule do not induce any increase in the 
accumulation of p21r~s-GTP.  Moreover, huB7 + L cells were 
not able to induce a hyperphosphorylation of Raf-1 or ERK2 
activation in T  cells. Collectively the GTP loading data and 
the Raf-1, ERK2 phosphorylations and ERK2 activation data 
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not initiate a Ras signaling pathway. 
TCR stimulation of p21 r~s is dependent on tyrosine ki- 
nase function (45). Two substrates for TCR. stimulated PTKs 
have been identified that may mediate the PTK effects on 
Ras, p95 ray and p36,  a protein that complexes to the SH2 
domain of the Grb2 adapter molecule, thus recruiting the 
guanine nucleotide exchange protein Sos (22, 23). CD28 li- 
gation with both the CD28 mAb CD28.2  and the ligand 
B7-1  apparently activated cellular PTK pathways as judged 
by Western blot analysis with an antiphosphotyrosine anti- 
body. We therefore explored whether the differences between 
CD28.2 and B7-1 with regard to p21 ras activation could be 
explained by differences in the ability of these CD28 ligands 
to modulate the tyrosine phosphorylation of Vav or p36. 
The data show that Vav is tyrosine phosphorylated in T 
cells activated via the TCR or CD28 irrespective of whether 
the CD28 mAb CD28.2 or the ligand B7-1 was used to trigger 
the CD28 receptor. The overall intensity of tyrosine phos- 
phoproteins in the TCR-activated cells was markedly higher 
than in  the B7-1-activated  cells.  In particular,  in  the an- 
tiphosphotyrosine blots of total cell lysates a 95-kD protein 
that migrates at a similar position to Vav is strongly tyrosine 
phosphorylated in TCR-activated cells and more weakly in 
T cells activated with huB7 + L cells (Fig.  4 D). This band 
probably represents multiple 95-kD tyrosine phosphoproteins 
because when Vav tyrosine phosphorylation was monitored 
directly, the relative effect of the TCR and B7-1 on Vav phos- 
phorylation was the opposite of that suggested by the anal- 
ysis of the 95-kD protein in total cell lysates. For direct anal- 
ysis of Vav tyrosine phosphorylation, Vav immunoprecipitates 
were probed with an antiphosphotyrosine antibody. These 
data confirm previous observations that triggering of the TCR 
stimulation induces a rapid but transient tyrosine phosphory- 
lation of Vav in T cells (37, 44). The ligand for CD28, B7-1, 
also induced Vav tyrosine phosphorylation but with an ap- 
parently  higher  stoichiometry  than  the  TCR  stimulus. 
Moreover,  compared with  the TCR  response,  the B7-1- 
induced tyrosine phosphorylation  of Vav was  a rapid but 
prolonged event. Previous studies have identified a 100-kD 
protein (ppl00)  as a substrate for CD28-activated PTKs in 
PMA-treated Jurkat cells (42, 43, 46). It is not known whether 
this ppl00 protein is Vav or another substrate.  The 95-kD 
tyrosine substrate seen in the present study may be the same 
as ppl00.  In the antiphosphotyrosine immunoblots of total 
lysates,  a 65-kD protein appeared selectively in the B7-1- 
activated cells, which supports the hypothesis that CD28 and 
the TCR may regulate different PTKs.  The present study 
illustrates  a  second  major  difference between  TCR  and 
CD28/PTK pathways by a difference in the magnitude and 
kinetics of p95 va~ tyrosine phosphorylation. 
Tyrosine phosphorylation of Vav regulates its in vitro gua- 
nine nucleotide exchange activity for Ras (22). However, one 
conclusion from the present data is that Vav tyrosine phos- 
phorylation is not sufficient to ensure activation of p21 r~s. 
In vivo,  this does not necessarily exclude that Vav tyrosine 
phosphorylation plays a role in Ras regulation.  First,  it is 
possible that regulation ofVav GTP exchange activity requires 
tyrosine phosphorylation of particular tyrosine residues and 
in the present study it was not established that Vav is phos- 
phorylated on identical sites in the TCR- and CD28-activated 
cells. Second, Vav tyrosine phosphorylation may be impor- 
tant for Ras regulation but there may be a simultaneous re- 
quirement for other signals that are triggered by the TCR 
and not by CD28. 
Sos, another guanine exchange factor for Ras, is detected 
in T  cells and interacts with an adaptor protein Grb2 (23, 
47). The complex of Sos/Grb2 is present in resting and ac- 
tive T  cells (Fig.  6) (23)  and the crucial regulatory step is 
the recruitment of the Grb2/Sos complex to the plasma mem- 
brane. Grb2 is translocated to the membrane by interactions 
between the Grb2-SH2 domain and tyrosine-phosphorylated 
proteins. The first example of this phenomenon was in fibro- 
blasts,  where EGF promotes the formation of a heterotri- 
meric complex of EGF receptor, Grb2 adaptor protein and 
Sos (26, 27). Upon TCR triggering a tyrosine-phosphorylated 
p36 protein complexes to the Grb2-SH2  domain and it is 
proposed that this p36 interaction recruits Grb2 and Sos to 
the membrane. The current data show that T cell activation 
with the CD28 mAb CD28.2 can also induce tyrosine phos- 
phorylation of a p36 Grb2-associated  protein. However, stim- 
ulation of T  cells with huB7 + L  cells does not have this 
effect. Thus the Grb2-associated p36 protein is not a sub- 
strate for B7-1-stimulated PTKs. Furthermore the tyrosine 
phosphorylation of p36 appears to correlate with activation 
of the Ras signaling pathway which supports the hypothesis 
that p36 is crucial for Ras activation. 
In fibroblasts another protein that can complex with the 
Grb2 SH2 domain is Shc (26).  Shc can bind to the TCR-~" 
chain and when it is tyrosine phosphorylated in TCR-activated 
cells, the formation of a Grb2/Shc complex has been observed 
(47).  In CD3-stimulated T cells, it seems difficult to detect 
tyrosine-phosphorylated Shc in association with Sos (23). This 
seems to reflect that the stoichiometry of Shc tyrosine phos- 
phorylation in TCR activated cells is low. Thus the only tyro- 
Table  1.  A  Comparison of Signal Transduction Pathways by a 
CD28 mAb CD28.2 and the CD28 Ligand B7-1 
CD28  stimulus 
Inducible events  Antibody  Ligand 
Tyrosine phosphorylation  of p95 wV  + 
Tyrosine phosphorylation of p36 
associated with the complex Sos/Grb2  + 
p21 raS activation  + 
Raf kinase hyperphosphorylation"  + 
MAP kinase phosphorylation *  + 
MAP kinase activationt  + 
Costimulatory  effects on IL-2 secretion  + 
+ 
+ 
Rating scale: -, not detectable; +, positive. 
* Determined by altered molecular  weight on SDS-PAGE gels. 
* Determined by MBP phosphorylation assay. 
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membrane-bound protein of 36 kD (23). In the present study, 
we did examine the effect of CD28.2 and B7-1 on Shc tyro- 
sine phosphorylation. CD28 mAb CD28.2 induced a level 
of Shc tyrosine phosphorylation that was lower than that 
seen in TCR-activated cells. It proved difficult to look at Shc 
phosphorylation in B7-1-stimulated T cells since the huB7 + 
L cells expressed constitutively tyrosine phosphorylated Shc 
(data not shown). 
Table 1 shows the signal transduction events triggered by 
a CD28 mAb and the ligand B7-1.  One conclusion is that 
Ras activation can be initiated when the CD28 molecule is 
triggered with a CD28 mAb but not the ligand B7-1. One 
explanation for the discrepancy in the intracellular signals trig- 
gered by the CD28 mAb CD28.2 and the ligand B7-1,  is 
that the CD28 mAb induces an artificially high degree of 
aggregation and cross-linking of the CD28 molecule that 
triggers a nonphysiological response. There are several prece- 
dents for signal transduction artifacts resulting from the in- 
appropriate cross-linking of receptor molecules (48). An al- 
ternative possibility is that the CD28 mAb CD28.2 reveals 
the full signaling potential of the CD28 receptor,  whereas 
the ligand B7-1 triggers one very important signaling pathway 
in T cells but it does not necessarily trigger the full stimula- 
tory potential of the CD28 receptor. Recently, another ligand 
for CD28 has been described, B7-2 (5-8). It has not yet been 
determined  whether  the  ligands  B7-1  and  B7-2  trigger 
common biochemical signals in cells. It is thus possible that 
the data obtained with the CD28 mAb CD28.2 reflect that 
B7-2 or indeed another ligand for CD28, as yet undefined, 
could use Ras-dependent signals to control T cell activation. 
It should be emphasized, however, that the CD28 costimula- 
tory pathway for IL-2 gene expression is induced when CD28 
is triggered with either the CD28 mAb CD28.2 or the ligand 
B7-1. Hence, the observation that CD28 ligation with anti- 
bodies  can  initiate  a  p21=s-dependent  signaling  cascade, 
whereas the natural ligand B7-1 cannot, suggests that p21 ras 
activation does not explain the costimulatory effects of CD28 
in terms of signal transduction. CD28 ligation with anti- 
bodies or B7-1 induces Vav tyrosine phosphorylation and if 
the relative tyrosine phosphorylation of Vav in B7-1 vs. TClk- 
activated cells has a functional purpose, then the data sug- 
gest that Vav will be more important for CD28 signal trans- 
duction than for TCR signals. 
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